Biolase falls on Nasdaq delisting notice

November 26

12/01/2023 13:54

** Shares of medical device maker Biolase Inc  BIOL.O  fall
7% premarket to $0.4 
    ** BIOL receives a notice that co has failed to satisfy a
continued listing rule on Nasdaq, by closing below $1/shr for 30
consecutive business days ended Jan 10
    ** Co has been provided an initial 180 calendar days till
July 10 to regain compliance
    ** BIOL had received a similar notice in May 2021, following
which it performed a 1-for-25 reverse stock split to regain
compliance 
    ** BIOL has declined 91% since stock started trading on
split-adjusted basis in April 2022
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))